Cargando…
Vascular endothelial growth factor in premenopausal women--indicator of the best time for breast cancer surgery?
Timing of surgery in premenopausal patients with breast cancer remains controversial. Angiogenesis is essential for tumour growth and vascular endothelial growth factor (VEGF) is one of the most potent angiogenic cytokines. We aimed to determine whether the study of VEGF in relation to the menstrual...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group|1
1998
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2062990/ https://www.ncbi.nlm.nih.gov/pubmed/9820181 |
_version_ | 1782137244750970880 |
---|---|
author | Heer, K. Kumar, H. Speirs, V. Greenman, J. Drew, P. J. Fox, J. N. Carleton, P. J. Monson, J. R. Kerin, M. J. |
author_facet | Heer, K. Kumar, H. Speirs, V. Greenman, J. Drew, P. J. Fox, J. N. Carleton, P. J. Monson, J. R. Kerin, M. J. |
author_sort | Heer, K. |
collection | PubMed |
description | Timing of surgery in premenopausal patients with breast cancer remains controversial. Angiogenesis is essential for tumour growth and vascular endothelial growth factor (VEGF) is one of the most potent angiogenic cytokines. We aimed to determine whether the study of VEGF in relation to the menstrual cycle could help further the understanding of this issue of surgical intervention. Fourteen premenopausal women were recruited, along with three post-menopausal women, a woman on an oral contraceptive pill and a single male subject. Between eight and 11 samples were taken per person, over one menstrual cycle (over 1 month in the five controls) and analysed for sex hormones and VEGF165. Serum VEGF was significantly lower in the luteal phase and showed a significant negative correlation with progesterone in all 14 premenopausal women. No inter-sample variations of VEGF were noted in the controls. Serum from both phases of the cycle from one subject was added to MCF-7 breast cancer cells; VEGF expression in the supernatant was lower in the cells to which the luteal phase serum was added. The lowering of a potent angiogenic cytokine in the luteal phase suggests a possible decreased potential for micrometastasis establishment in that phase. This fall in VEGF may be an effect of progesterone and should be the focus of future studies. |
format | Text |
id | pubmed-2062990 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 1998 |
publisher | Nature Publishing Group|1 |
record_format | MEDLINE/PubMed |
spelling | pubmed-20629902009-09-10 Vascular endothelial growth factor in premenopausal women--indicator of the best time for breast cancer surgery? Heer, K. Kumar, H. Speirs, V. Greenman, J. Drew, P. J. Fox, J. N. Carleton, P. J. Monson, J. R. Kerin, M. J. Br J Cancer Research Article Timing of surgery in premenopausal patients with breast cancer remains controversial. Angiogenesis is essential for tumour growth and vascular endothelial growth factor (VEGF) is one of the most potent angiogenic cytokines. We aimed to determine whether the study of VEGF in relation to the menstrual cycle could help further the understanding of this issue of surgical intervention. Fourteen premenopausal women were recruited, along with three post-menopausal women, a woman on an oral contraceptive pill and a single male subject. Between eight and 11 samples were taken per person, over one menstrual cycle (over 1 month in the five controls) and analysed for sex hormones and VEGF165. Serum VEGF was significantly lower in the luteal phase and showed a significant negative correlation with progesterone in all 14 premenopausal women. No inter-sample variations of VEGF were noted in the controls. Serum from both phases of the cycle from one subject was added to MCF-7 breast cancer cells; VEGF expression in the supernatant was lower in the cells to which the luteal phase serum was added. The lowering of a potent angiogenic cytokine in the luteal phase suggests a possible decreased potential for micrometastasis establishment in that phase. This fall in VEGF may be an effect of progesterone and should be the focus of future studies. Nature Publishing Group|1 1998-11 /pmc/articles/PMC2062990/ /pubmed/9820181 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Research Article Heer, K. Kumar, H. Speirs, V. Greenman, J. Drew, P. J. Fox, J. N. Carleton, P. J. Monson, J. R. Kerin, M. J. Vascular endothelial growth factor in premenopausal women--indicator of the best time for breast cancer surgery? |
title | Vascular endothelial growth factor in premenopausal women--indicator of the best time for breast cancer surgery? |
title_full | Vascular endothelial growth factor in premenopausal women--indicator of the best time for breast cancer surgery? |
title_fullStr | Vascular endothelial growth factor in premenopausal women--indicator of the best time for breast cancer surgery? |
title_full_unstemmed | Vascular endothelial growth factor in premenopausal women--indicator of the best time for breast cancer surgery? |
title_short | Vascular endothelial growth factor in premenopausal women--indicator of the best time for breast cancer surgery? |
title_sort | vascular endothelial growth factor in premenopausal women--indicator of the best time for breast cancer surgery? |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2062990/ https://www.ncbi.nlm.nih.gov/pubmed/9820181 |
work_keys_str_mv | AT heerk vascularendothelialgrowthfactorinpremenopausalwomenindicatorofthebesttimeforbreastcancersurgery AT kumarh vascularendothelialgrowthfactorinpremenopausalwomenindicatorofthebesttimeforbreastcancersurgery AT speirsv vascularendothelialgrowthfactorinpremenopausalwomenindicatorofthebesttimeforbreastcancersurgery AT greenmanj vascularendothelialgrowthfactorinpremenopausalwomenindicatorofthebesttimeforbreastcancersurgery AT drewpj vascularendothelialgrowthfactorinpremenopausalwomenindicatorofthebesttimeforbreastcancersurgery AT foxjn vascularendothelialgrowthfactorinpremenopausalwomenindicatorofthebesttimeforbreastcancersurgery AT carletonpj vascularendothelialgrowthfactorinpremenopausalwomenindicatorofthebesttimeforbreastcancersurgery AT monsonjr vascularendothelialgrowthfactorinpremenopausalwomenindicatorofthebesttimeforbreastcancersurgery AT kerinmj vascularendothelialgrowthfactorinpremenopausalwomenindicatorofthebesttimeforbreastcancersurgery |